Genetics and Pathophysiology of Neurodegeneration with Brain Iron Accumulation (NBIA)
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Our understanding of the syndromes of Neurodegeneration with Brain Iron Accumulation (NBIA) continues to grow considerably. In addition to the core syndromes of pantothenate kinase-associated neurodegeneration (PKAN, NBIA1) and PLA2G6-associated neurodegeneration (PLAN, NBIA2), several other genetic causes have been identified (including FA2H, C19orf12, ATP13A2, CP and FTL). In parallel, the clinical and pathological spectrum has broadened and new age-dependent presentations are being described. There is also growing recognition of overlap between the different NBIA disorders and other diseases including spastic paraplegias, leukodystrophies and neuronal ceroid lipofuscinosis which makes a diagnosis solely based on clinical findings challenging. Autopsy examination of genetically-confirmed cases demonstrates Lewy bodies, neurofibrillary tangles, and other hallmarks of apparently distinct neurodegenerative disorders such as Parkinson's disease (PD) and Alzheimer's disease. Until we disentangle the various NBIA genes and their related pathways and move towards pathogenesis-targeted therapies, the treatment remains symptomatic. Our aim here is to provide an overview of historical developments of research into iron metabolism and its relevance in neurodegenerative disorders. We then focus on clinical features and investigational findings in NBIA and summarize therapeutic results reviewing reports of iron chelation therapy and deep brain stimulation. We also discuss genetic and molecular underpinnings of the NBIA syndromes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mitochondrial Dysfunction and Oxidative Stress in Neurodegenerative Diseases
Lin, M. T., & Beal, M. F. (2006) · Nature · doi:10.1038/nature05292 · Cited by 6,455 · cited 1×
“PANK2 is mainly targeted to mitochondria, its mutation may therefore also cause dysfunction of cellular energy metabolism [73].”
The effect of age on the non-haemin iron in the human brain
Hallgren, B., & Sourander, P. (1958) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1958.tb12607.x · Cited by 1,427
Ramirez, A., Heimbach, A., Gründemann, J., Stiller, B., Hampshire, D., Cid, L. P., Goebel, I., Mubaidin, A. F., Wriekat, A.-L., Roeper, J., et al. (2006) · Nature Genetics · doi:10.1038/ng1884 · Cited by 1,208
Blood–brain barrier: Ageing and microvascular disease – systematic review and meta-analysis
Farrall, A. J., & Wardlaw, J. M. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2007.07.015 · Cited by 882
Copper and iron disorders of the brain
Madsen, E., & Gitlin, J. D. (2007) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.30.051606.094232 · Cited by 557 · cited 1×
“from Madsen and Gitlin [192] and reproduced from [3].”
Kell, D. B. (2009) · BMC Medical Genomics · doi:10.1186/1755-8794-2-2 · Cited by 554
Snowden, J. S., Rollinson, S., Thompson, J. C., Harris, J. M., Stopford, C. L., Richardson, A. M. T., Jones, M., Gerhard, A., Davidson, Y. S., Robinson, A., et al. (2012) · Brain · doi:10.1093/brain/awr355 · Cited by 523
Cellular distribution of transferrin, ferritin, and iron in normal and aged human brains
Connor, J. R., Menzies, S. L., Martin, S. M. S., & Mufson, E. J. (1990) · Journal of Neuroscience Research · doi:10.1002/jnr.490270421 · Cited by 472 · cited 2×
“Between different cell types and between different brain regions iron content varies considerably with high concentrations in oligodendrocytes, particularly in the cortex and cortico-subcortical junction, and low concentrations in neurons and astrocytes [5].”
Zecca, L., Gallorini, M., Schünemann, V., Trautwein, A. X., Gerlach, M., Riederer, P., Vezzoni, P., & Tampellini, D. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00186.x · Cited by 401 · cited 1×
“Essentially no iron is detectable in the brain at birth [7-9], but iron then accumulates during development.”
Clinical and genetic delineation of neurodegeneration with brain iron accumulation
Gregory, A., Polster, B. J., & Hayflick, S. J. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.061929 · Cited by 364 · cited 1×
“Iron deposits in the SN are present in some atypical cases [98,99].”
Kell, D. B. (2010) · Archives of Toxicology · doi:10.1007/s00204-010-0577-x · Cited by 361 · cited 1×
“However, to a milder degree iron is also present in other conditions including Parkinson’s disease [31,32] (mainly affecting the substantia nigra) and atypical parkinsonian disorders, Friedreich ataxia and multiple sclerosis (for extensive review see [33]).”
Tracking iron in multiple sclerosis: a combined imaging and histopathological study at 7 Tesla
Bagnato, F., Hametner, S., Yao, B., van Gelderen, P., Merkle, H., Cantor, F. K., Lassmann, H., & Duyn, J. H. (2011) · Brain · doi:10.1093/brain/awr278 · Cited by 351
Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation
Chinnery, P. F., Crompton, D. E., Birchall, D., Jackson, M. J., Coulthard, A., Lombes, A., Quinn, N., Wills, A., Fletcher, N., Mottershead, J. P., et al. (2006) · Brain · doi:10.1093/brain/awl319 · Cited by 205
ATP13A2 regulates mitochondrial bioenergetics through macroautophagy
Gusdon, A. M., Zhu, J., Van Houten, B., & Chu, C. T. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.015 · Cited by 167 · cited 1×
“More recent functional studies strengthened the role of ATP13A2 for mitochondrial renewal and maintenance when decreased autophagy was observed in ATP13A2-deficicent cells which led to increase of mitochondrial mass, secondarily affected mitochondrial quality control and resulted in increased ROS production [138].”
Neuroferritinopathy: a new inborn error of iron metabolism
Keogh, M. J., Jonas, P., Coulthard, A., Chinnery, P. F., & Burn, J. (2012) · Neurogenetics · doi:10.1007/s10048-011-0310-9 · Cited by 49
Long-term improvement under deferiprone in a case of neurodegeneration with brain iron accumulation
Kwiatkowski, A., Ryckewaert, G., Jissendi Tchofo, P., Moreau, C., Vuillaume, I., Chinnery, P. F., Destée, A., Defebvre, L., & Devos, D. (2012) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2011.06.024 · Cited by 41 · cited 1×
“This suggests that unknown diagnosis may not necessarily prevent initiation of chelating treatment [185-187].”
Neurodegeneration with brain iron accumulation
Dusek, P., & Schneider, S. A. (2012) · Current Opinion in Neurology · doi:10.1097/wco.0b013e3283550cac · Cited by 39
Self-citation
Cited by
The role of iron in brain ageing and neurodegenerative disorders
Ward, R. J., Zucca, F. A., Duyn, J. H., Crichton, R. R., & Zecca, L. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70117-6 · Cited by 1,819
An autoradiographic evaluation of AV-1451 Tau PET in dementia
Lowe, V. J., Curran, G., Fang, P., Liesinger, A. M., Josephs, K. A., Parisi, J. E., Kantarci, K., Boeve, B. F., Pandey, M. K., Bruinsma, T., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0315-6 · Cited by 474
Brain iron is associated with accelerated cognitive decline in people with Alzheimer pathology
Ayton, S., Wang, Y., Diouf, I., Schneider, J. A., Brockman, J., Morris, M. C., & Bush, A. I. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0375-7 · Cited by 365
Sensory aspects of movement disorders
Patel, N., Jankovic, J., & Hallett, M. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70213-8 · Cited by 343
Self-citationLevi, S., & Tiranti, V. (2019) · Pharmaceuticals · doi:10.3390/ph12010027 · Cited by 90
“PKAN accounts for a large fraction of NBIA cases [44] while CoPAN appears more rare, being so far identified in few individuals worldwide [45–48].”
Background
Metadata
- Authors
- A. Schneider, S., Dusek, P., Hardy, J., Westenberger, A., Jankovic, J., & P. Bhatia, K.
- Venue
- Current Neuropharmacology
- Publisher
- Bentham Science Publishers Ltd.
- Published
- 2013-01-01
- Volume
- 11
- Issue
- 1
- Pages
- 59-79
- ISSN
- 1570-159X (ISSN-L)
- OpenAlex
- W2055428417
- Cited by
- 139
- References
- 17
- FWCI
- 9.96
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.